Innate Immunity in the Pathogenesis of Lupus and Antiphospholipid Vasculopathy
狼疮和抗磷脂血管病发病机制中的先天免疫
基本信息
- 批准号:8751822
- 负责人:
- 金额:$ 12.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-05 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:African AmericanAnimal ModelAntiphospholipid AntibodiesAntiphospholipid SyndromeAttentionAutoimmune DiseasesAutoimmune ProcessAutoimmunityAutomobile DrivingAwardBasic ScienceBinding ProteinsBloodBlood PlateletsBlood VesselsBlood coagulationCardiovascular DiseasesCardiovascular systemChromatinClinicClinicalConsultationsDNA-Binding ProteinsDataDendritic CellsDependenceDevelopmentDiseaseEndothelial CellsEnvironmentEventFeedbackFemaleFemale of child bearing ageFlow CytometryFosteringFundingGeneral PopulationGoalsHealthHemostatic functionHumanImmune responseImmunologistIn VitroInflammationInjuryInstitutesInstitutionInstitutional Review BoardsInstructionInterferon Type IInterferonsKidneyLettersLifeLinkLupusMediatingMediator of activation proteinMedical ResearchMedicineMegakaryocytesMentorsMentorshipMichiganMicroscopyModelingMusNatural ImmunityNeutrophil ActivationOrganPathogenesisPathologicPatientsPharmaceutical PreparationsPhospholipidsPlasmaPlayPositioning AttributeProteinsRecording of previous eventsResearchResearch ActivityResearch PersonnelResearch ProposalsRheumatismRheumatologyRiskRoleSamplingScholarshipSerumSignal PathwaySignal TransductionSystemic Lupus ErythematosusTestingThrombocytopeniaThromboplastinThrombosisTimeTrainingUniversitiesVascular DiseasesVenous ThrombosisWorkWritingantimicrobialbeta 2-glycoprotein Icardiovascular disorder riskcardiovascular risk factorcareercareer developmentcellular imagingeducation evaluationextracellularfetalfield studyhuman subjectimprovedin vivoinhibitor/antagonistkillingslecturermalemonocyteneutrophiloral communicationpathogenprofessorprogramspublic health relevanceresponseskillsstatistical centersymposiumsystemic autoimmune diseaseundergraduate research
项目摘要
ABSTRACT
Patients with systemic lupus erythematosus (SLE) and the related antiphospholipid syndrome (APS) are
predisposed to life-threatening thrombotic events. Neutrophils, and in particular neutrophil extracellular traps
(NETs), have recently been linked to both active SLE and thrombosis. The possibility that NETs might be an
important trigger of thrombosis in autoimmune disease patients has not, however, been rigorously evaluated.
This award will play a critical role in helping me achieve my long-term career goals, which include: (1)
becoming an expert in SLE and APS pathogenesis, especially the interplay between innate immune responses
and thrombosis, (2) establishing a career as an independent investigator at a leading medical research
institution, and (3) mentoring and fostering the development of trainees. These objectives will be reached by
incorporating both a strong mentorship environment and a formal instructional plan. The plan focuses on
specific scientific and career development goals.
Mentorship Environment: I am currently a Clinical Lecturer in the Division of Rheumatology at the University
of Michigan. I will become a tenure-track Assistant Professor on January 1, 2014. With this promotion, my
time will be protected for research with just one-half day of clinic per week. Further, as is detailed in the Letter
of Institutional Support, substantial start-up funds will be provided to support my research activities. Over the
past two years, I have received strong training from Dr. Mariana Kaplan as an immunologist. In this proposal, I
am seeking support for a significantly new research endeavor, as I turn my attention to the pathologic
thrombosis inherent to systemic autoimmune diseases such as SLE. Dr. David Pinsky, an expert in
cardiovascular medicine and the interplay between inflammation and thrombosis, will be my primary research
mentor going forward.
Formal Instruction: My scientific goals include: (1) applying models of neutrophil activation and thrombosis
to the rheumatic diseases, (2) working effectively and efficiently with patient samples, and (3) mechanistically
studying platelet signaling and activation. Basic science coursework will be through several centers at the
University of Michigan including the Center for Statistical Consultation and Research, the Flow Cytometry
Core, and the Center for Live Cell Imaging. I also plan to regularly attend the intensive Symposium on
Hemostasis, held biennially in Chapel Hill, NC. Equally important are my career development goals, which
include: (1) improving written and oral communication skills, (2) developing IRB proposals for research on
human subjects, and (3) enriching my mentoring skills. Specific instructional programs and courses will be
utilized including the Michigan Institute for Clinical and Health Research, IRBMED, the Program for Education
and Evaluation in Responsible Research and Scholarship, and the Undergraduate Research Opportunity
Program.
Research: Globally, I plan to explore the hypothesis that exaggerated NET formation is an important mediator
of pathologic thrombosis in SLE and APS patients. Aim 1 will study the role of antiphospholipid antibodies (the
hallmark of APS, and also frequently found in SLE) in activating neutrophils to release NETs. Aim 2 will
explore the extent to which SLE platelets interact with neutrophils to promote NET formation. Aim 3 will build
on the human studies of Aims 1 and 2 by testing the importance of neutrophils and platelets in animal models
of autoimmune-mediated thrombosis and vascular damage.
抽象的
患有系统性红斑狼疮 (SLE) 和相关抗磷脂综合征 (APS) 的患者
容易发生危及生命的血栓事件。中性粒细胞,特别是中性粒细胞胞外陷阱
(NET),最近被认为与活动性 SLE 和血栓形成有关。 NET 的可能性
然而,尚未对自身免疫性疾病患者血栓形成的重要触发因素进行严格评估。
该奖项将在帮助我实现长期职业目标方面发挥关键作用,其中包括:(1)
成为 SLE 和 APS 发病机制的专家,特别是先天免疫反应之间的相互作用
和血栓形成,(2) 在领先的医学研究中建立独立调查员的职业生涯
(3) 指导和促进学员的发展。这些目标将通过
结合强大的指导环境和正式的教学计划。该计划的重点是
具体的科学和职业发展目标。
导师环境:我目前是大学风湿病科的临床讲师
密歇根州。我将于 2014 年 1 月 1 日成为终身教授助理教授。通过这次晋升,我的
每周只有半天的门诊时间,可以节省研究时间。此外,正如信中详细说明的那样
机构支持,将提供大量启动资金来支持我的研究活动。超过
在过去的两年里,我作为免疫学家接受了玛丽安娜·卡普兰博士的严格培训。在这个提案中,我
当我将注意力转向病理学时,正在寻求对一项重大新研究工作的支持
系统性自身免疫性疾病(如 SLE)固有的血栓形成。 David Pinsky 博士,专家
心血管医学以及炎症和血栓形成之间的相互作用将是我的主要研究
前进的导师。
正式指示:我的科学目标包括:(1)应用中性粒细胞活化和血栓形成模型
针对风湿性疾病,(2) 有效且高效地处理患者样本,以及 (3) 机械地
研究血小板信号传导和激活。基础科学课程将通过多个中心进行
密歇根大学,包括统计咨询和研究中心、流式细胞仪
核心和活细胞成像中心。我还计划定期参加关于
止血,每两年在北卡罗来纳州教堂山举行一次。同样重要的是我的职业发展目标,
包括:(1) 提高书面和口头沟通技巧,(2) 制定 IRB 研究建议
人类受试者,以及(3)丰富我的指导技能。具体的教学计划和课程将
所利用的机构包括密歇根临床与健康研究所、IRBMED、教育计划
负责任的研究和奖学金以及本科生研究机会的评估
程序。
研究:在全球范围内,我计划探索夸大的 NET 形成是重要中介因素的假设
SLE 和 APS 患者的病理性血栓形成。目标 1 将研究抗磷脂抗体(
APS 的标志,也常见于 SLE),可激活中性粒细胞释放 NET。目标2将
探讨 SLE 血小板与中性粒细胞相互作用促进 NET 形成的程度。目标 3 将建立
通过在动物模型中测试中性粒细胞和血小板的重要性来研究目标 1 和 2 的人体研究
自身免疫介导的血栓形成和血管损伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Knight其他文献
Jason Knight的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Knight', 18)}}的其他基金
NETs as therapeutic targets in obstetric APS
NETs 作为产科 APS 的治疗靶点
- 批准号:
10786977 - 财政年份:2023
- 资助金额:
$ 12.84万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10364621 - 财政年份:2018
- 资助金额:
$ 12.84万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10581346 - 财政年份:2018
- 资助金额:
$ 12.84万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10168724 - 财政年份:2018
- 资助金额:
$ 12.84万 - 项目类别:
Innate Immunity in the Pathogenesis of Lupus and Antiphospholipid Vasculopathy
狼疮和抗磷脂血管病发病机制中的先天免疫
- 批准号:
9392606 - 财政年份:2014
- 资助金额:
$ 12.84万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
脆性X综合征动物模型中异常视觉信息处理和视觉注意力的神经环路机制研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
自身抗体作为治疗后莱姆病综合征的预测标记
- 批准号:
10737996 - 财政年份:2023
- 资助金额:
$ 12.84万 - 项目类别:
Thromboinflammatory consequences of infection-induced autoimmunity
感染引起的自身免疫的血栓炎症后果
- 批准号:
10672980 - 财政年份:2022
- 资助金额:
$ 12.84万 - 项目类别:
Thromboinflammatory consequences of infection-induced autoimmunity
感染引起的自身免疫的血栓炎症后果
- 批准号:
10524822 - 财政年份:2022
- 资助金额:
$ 12.84万 - 项目类别:
Purinergic modulation of the autoimmune vascular phenotype
自身免疫血管表型的嘌呤能调节
- 批准号:
10581346 - 财政年份:2018
- 资助金额:
$ 12.84万 - 项目类别:
TNF-alpha Blockade with Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS
使用 Certolizumab 阻断 TNF-α 可预防 APS 高危患者的妊娠并发症
- 批准号:
10175669 - 财政年份:2016
- 资助金额:
$ 12.84万 - 项目类别: